• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Expression of CD44 variant 9 in rectal cancer after treatment of neoadjuvant chemotradiotherapy

Research Project

Project/Area Number 26462004
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Digestive surgery
Research InstitutionUniversity of Tsukuba

Principal Investigator

Enomoto Tsuyoshi  筑波大学, 医学医療系, 講師 (10628762)

Co-Investigator(Renkei-kenkyūsha) OHKOHCHI Nobuhiro  筑波大学, 医学医療系, 教授 (40213673)
ODA Tatsuya  筑波大学, 医学医療系, 教授 (20282353)
MURATA Soichiro  横浜市立大学, 大学院医学研究科, 准教授 (40436275)
TAKEUCHI Tomoyo  筑波大学, 医学医療系, 助教 (50450333)
Project Period (FY) 2014-04-01 – 2017-03-31
Project Status Completed (Fiscal Year 2016)
Budget Amount *help
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords直腸癌 / 術前化学放射線療法 / CD44variant 9 / 癌幹細胞 / 大腸癌 / 新規診断法 / CD44v9 / 直腸癌局所再発
Outline of Final Research Achievements

Introduction: CD44 variant 9 is important factor of cancer stem cell in colorectal cancer, however, its clinical role is uncertain.Aims: Objective of this study is to evaluate the immune-histochemical expression of CD44 variant 9 as stem cell marker in the colorectal cancer after treatment of neoadjuvant chemoradiotherapy (NCRT). Material and Methods: This study included 20 rectal specimens. All specimens were underwent NCRT. Clinical data were available for all case.Result: Average score of Expression of CD44 after NCRT is 0.93 (0-2.4). Expression score of CD44 variant 9 is in proportion to efficacy of pathological grade; grade2/ 1a/ 0 is 0.3/1.6/2, respectively. However, Expression score of relapse patient, non-relapse patient is 0.8 and 0.93, respectively. The correlation between relapse of tumor and expression of CD44 variant 9 is not significant.Conclusion: Expression of CD44 variant 9 might be associated with treatment effect of NCRT, however, no relation to prognosis.

Report

(4 results)
  • 2016 Annual Research Report   Final Research Report ( PDF )
  • 2015 Research-status Report
  • 2014 Research-status Report
  • Research Products

    (5 results)

All 2016 2015 2014

All Presentation (5 results)

  • [Presentation] 当科における下部直腸癌根治切除後局所再発の検討2016

    • Author(s)
      榎本剛史
    • Organizer
      第116回 日本外科学会定期学術集会
    • Place of Presentation
      大阪国際会議場(大阪)
    • Year and Date
      2016-04-14
    • Related Report
      2015 Research-status Report
  • [Presentation] 当科における下部直腸癌根治切除後局所再発の検討2016

    • Author(s)
      榎本剛史
    • Organizer
      第116回 日本外科学会定期学術集会
    • Place of Presentation
      大阪国際会議場(大阪府大阪市)
    • Related Report
      2016 Annual Research Report
  • [Presentation] 局所進行直腸癌に対する治療戦略2016

    • Author(s)
      榎本剛史
    • Organizer
      つくばcancer arena
    • Place of Presentation
      筑波大学(茨城県つくば市)
    • Related Report
      2016 Annual Research Report
  • [Presentation] 直腸癌における術前化学放射線施行症例における手術部位感染2015

    • Author(s)
      榎本剛史
    • Organizer
      第115回 日本外科学会定期学術集会
    • Place of Presentation
      名古屋国際会議場(愛知県名古屋市)
    • Year and Date
      2015-04-16
    • Related Report
      2015 Research-status Report
  • [Presentation] 局所進行直腸癌における術前治療前後での腫瘍組織中CD44v9の発現2014

    • Author(s)
      榎本剛史
    • Organizer
      第114回 日本外科学会定期学術集会
    • Place of Presentation
      国立京都国際会館(京都府京都市)
    • Year and Date
      2014-04-04
    • Related Report
      2014 Research-status Report

URL: 

Published: 2014-04-04   Modified: 2018-03-22  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi